Aytu BioPharma, Inc.

NasdaqCM:AYTU Stock Report

Market Cap: US$10.7m

Aytu BioPharma Future Growth

Future criteria checks 3/6

Aytu BioPharma's revenue is forecast to decline at 7.8% per annum while its annual earnings are expected to grow at 91.2% per year. EPS is expected to grow by 127.6% per annum.

Key information

91.2%

Earnings growth rate

127.6%

EPS growth rate

Pharmaceuticals earnings growth24.0%
Revenue growth rate-7.8%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Nov 2024

Recent future growth updates

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Recent updates

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

Earnings and Revenue Growth Forecasts

NasdaqCM:AYTU - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2026703N/AN/A1
6/30/2025684N/AN/A1
6/30/202481-16-1-1N/A
3/31/202494-1499N/A
12/31/202398-1866N/A
9/30/2023102-2444N/A
6/30/2023107-17-5-5N/A
3/31/2023104-31-22-22N/A
12/31/2022106-77-28-28N/A
9/30/2022102-82-34-34N/A
6/30/202297-109-29-29N/A
3/31/202293-112-30-28N/A
12/31/202182-84-30-28N/A
9/30/202174-82-24-22N/A
6/30/202166-58-28-26N/A
3/31/202157-42-27-27N/A
12/31/202052-22-30-30N/A
9/30/202040-13-33-33N/A
6/30/202028-14-28-28N/A
3/31/202014-25-24-24N/A
12/31/20199-24-16-16N/A
9/30/20197-29-14-14N/A
6/30/20197-27-14-14N/A
3/31/20197-12-16-15N/A
12/31/20185-10-17-16N/A
9/30/20184-9-15-14N/A
6/30/20184-10-16-16N/A
3/31/20184-17N/A-15N/A
12/31/20174-20N/A-13N/A
9/30/20174-21N/A-13N/A
6/30/20173-23N/A-14N/A
3/31/20173-31N/A-13N/A
12/31/20163-33N/A-13N/A
9/30/20163-32N/A-14N/A
6/30/20163-28N/A-11N/A
3/31/20162-15N/A-10N/A
12/31/20151-10N/A-9N/A
9/30/20151-8N/A-7N/A
6/30/20150-8N/A-7N/A
3/31/20150-7N/A-7N/A
12/31/20140-7N/A-7N/A
6/30/20140-6N/A-6N/A
12/31/20130-4N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AYTU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: AYTU is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AYTU is expected to become profitable in the next 3 years.

Revenue vs Market: AYTU's revenue is expected to decline over the next 3 years (-7.8% per year).

High Growth Revenue: AYTU's revenue is forecast to decline over the next 3 years (-7.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AYTU's Return on Equity is forecast to be high in 3 years time


Discover growth companies